APEIRON Biologics AG

Founded

2005

Staff

37

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

human health

APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON Biologics´ projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.

R&D:APN01 (alunacedase alfa; rhsACE2), a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2, has three distinct potential benefits to treat COVID-19 and has completed a double blind, placebo-controlled Phase II trial in Europe and Russia. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd.

Production:APN401´s proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid tumors. The clinical program is a first-in-class ambulatory autologous cellular therapy to strengthen immune reactivity via an intracellular master checkpoint inhibitor, Cbl-b.